Guillain-Barre syndrome (GBS) is a rare autoimmune disorder in which the body's immune system attacks the peripheral nerves, leading to muscle weakness and paralysis. It accounts for approximately 0.38 to 2.53 cases per 100,000 person-years worldwide. There is a significant unmet clinical need for improved therapies, as current treatment options, such as intravenous immunoglobulin (IVIG) and plasma exchange, have limitations. The growing emphasis on novel immunomodulatory approaches and targeted Guillain-Barre syndrome therapeutic products is expected to drive pipeline growth. Promising drug candidates, including monoclonal antibodies and complement inhibitors, are under investigation to improve patient outcomes.
Major companies involved in the Guillain-Barre syndrome drugs market include Argenx, Annexon, Inc., and others.
Leading drugs currently in the pipeline include Efgartigimod, ANX005, Imlifidase, and others.
The advancements in immunotherapy, increasing research on novel treatments, and growing investment in monoclonal antibodies are likely to positively impact the Guillain-Barré syndrome pipeline landscape.
The Guillain-Barre Syndrome Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into Guillain-Barre syndrome therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Guillain-Barre syndrome. The Guillain-Barre syndrome report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Guillain-Barre syndrome pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Guillain-Barre syndrome treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Guillain-Barre syndrome.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Guillain-Barre syndrome is a rare autoimmune disorder where the body's immune system attacks the peripheral nervous system, leading to muscle weakness, paralysis, and, in severe cases, respiratory failure. It often follows an infection, such as a respiratory or gastrointestinal illness, which triggers the immune response that damages nerve tissues.
Treatment for Guillain-Barre syndrome focuses on managing symptoms and accelerating recovery. Current therapies include intravenous immunoglobulin (IVIG) and plasma exchange, both aimed at reducing the immune response. Supportive care, such as respiratory assistance, may be necessary for severe cases, while physical therapy helps in regaining strength and mobility.
A 2024 study reports that Guillain-Barré syndrome incidence varies globally, ranging from 0.38 to 2.53 cases per 100,000 individuals annually. European and North American populations show annual incidences between 0.84 and 1.91 per 100,000, while incidences in Asian populations, such as Japan, are notably lower at 0.44 per 100,000 individuals. These epidemiological findings inform ongoing therapeutic developments for Guillain-Barré syndrome.
This section of the report covers the analysis of Guillain-Barre syndrome drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phases II and IV encompass a significant share of the total Guillain-Barre syndrome clinical trials
The drug molecule categories covered under the Guillain-Barre syndrome pipeline analysis include monoclonal antibodies, small molecules, gene therapies, biologics, plasma-derived therapies, and others. The Guillain-Barre syndrome report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Guillain-Barre syndrome.
The EMR report for the Guillain-Barre syndrome drug pipeline covers the profiles of key companies involved in clinical trials and their drugs under development. It provides a detailed Guillain-Barre syndrome therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Guillain-Barre syndrome clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Guillain-Barre syndrome. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Guillain-Barre syndrome drug candidates.
The Phase III study, sponsored by Annexon, Inc., evaluates the efficacy and safety of ANX005, a first-in-class C1q blocking antibody, in Guillain-Barré syndrome (GBS). The trial met its primary endpoint, demonstrating a 2.4-fold improvement in Guillain-Barré syndrome -disability scale at week 8. ANX005 showed early and sustained benefits, including improved muscle strength, reduced nerve damage, and shorter ventilation dependency.
The Phase III clinical trial, sponsored by Chafic Karam at the University of Pennsylvania, evaluates the safety and efficacy of Efgartigimod in Guillain-Barré syndrome (GBS) patients. The study aims to determine whether Efgartigimod improves patient outcomes. The study is expected to be completed by May 2027 and will enroll around 30 participants.
Hansa Biopharma’s investigational drug, Imlifidase, has shown promising results in treating Guillain-Barré syndrome (GBS). The objective of this Phase II study (15-HMedIdeS-09) was to examine the drug’s efficacy in improving motor function. Patients receiving Imlifidase with IVIg regained independent walking in 16 days, nearly six weeks faster than those treated with IVIg alone in the IGOS study.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Guillain-Barre Syndrome Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Guillain-Barre syndrome. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Guillain-Barre syndrome collaborations, regulatory environments, and potential growth opportunities.
Global Guillain-Barre Syndrome Treatment Market
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share